Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2007

View Archived Issues

Novel oncolytic drugs revealed in recent patent literature

Phase I studies of AVE-9633, AVE-1642 reported

Studies show benefit with quetiapine in bipolar and borderline personality disorders

Cognition improved in schizophrenic patients given rivastigmine

Sirtris reports positive data from study of SIRT1 in preclinical model of type 2 diabetes

Recent patents report new antiobesity agents

Cleveland BioLabs reports positive results from mouse study of CBLB-612

Discovery of novel analgesic agents reported

Inhibitex reports positive results from phase I clinical trial of FV-100

Wyeth Pharmaceuticals submits clinical study reports of Viviant to supplement pending NDA

IDM Pharma provides update on development of mifamurtide, Uvidem and IDM-2101

Anti-KIR monoclonal antibody enhances NK cell killing activity in vitro and in vivo

Improved pharmacokinetic profile of novel recombinant FVII fusion protein

Shire acquires rights to AT-1001 from Alba Therapeutics

DiaMedica receives Polish regulatory clearance for phase II human study of DM-83

T cells expressing costimulatory ligands, a novel approach in cancer immunotherapy

GlaxoSmithKline exercises option to further develop and commercialize Exelixis' XL-880

Pharmexa updates and extends research and license agreement with Lundbeck for PX-106

Oncothyreon to receive payment through Stimuvax agreement with Merck KGaA

Ambrx enters collaboration agreement with Lilly for novel drug treatments

Actelion reports preliminary data from bosentan proof-of-concept cancer study

Biovitrum successfully completes phase I BVT-74316 study

Idera and Merck KGaA collaborate on development of TLR9 agonists for cancer

Phase IIa study commences for delta opioid agonist ADL-5859 in neuropathic pain

Kiadis Pharma successfully completes end of phase II meeting with FDA for Reviroc

Positive interim results reported from Rapinyl phase III clinical trial

Lundbeck and Takeda advance Lu-AA-21004 into phase III

Genzyme is granted European CE mark for single-treatment Synvisc-One for osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...